Philadelphia, PA – Plexus Ventures, a global pharmaceutical consulting firm, announces its collaboration with Celon Pharma SA, Łomianki, Poland.
Michael O’Sullivan Managing Partner London Office, noted: “We are very pleased to provide continuing support to an important emerging company in the Polish market.”
Additional details regarding the transaction are provided in Celon’s press release:
Celon Pharma SA finalized an agreement with Plexus Ventures
2017/08/07: Under the terms of the Agreement, Plexus Ventures will develop a development strategy for drug candidates and will hold meetings with potential partners. In the event of significant clinical progress and consent of the parties to the drug development strategy, Plexus Ventures will take steps to acquire partners for development or licensees or to sell the Company’s innovative drug distribution rights. The choice of a specific strategy for the product will be related to the market and investment characteristics of the drug’s development. Licensing or selling of rights to distribution of innovative medicines Celon Pharma SA may take place at the turn of 2018/2019.
Dr. Maciej Wieczorek, President of the Management Board of Celon Pharma SA: The agreement with Plexus Ventures confirms the legitimacy of further development of selected candidates for drugs that have the potential of being the first in their therapeutic class or having significant competitive characteristics. Developed products can achieve global sales potential of more than $ 0.5 billion per year and some of them over $ 2 billion per year.
At the same time, the Company has plans for sustainable, independent commercialization of its own specialized medicines on the world markets.
